Remepy is pioneering Hybrid Drugs: traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments. Remepy has already proven in human studies the effect of its products, using extensive brain imaging, as well as blood and saliva samples, with promising results for Oncology, MCI, and Parkinson's Disease. Their approach offers an efficient method to create new proprietary pharma assets, unlocking an entire new market and world of data. The Remepy team includes top scientists, physicians, and technologists.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/01/24	$15,000,000	Seed	Firstime Venture Capital NFX PsyMed Ventures Supernode Ventures Vine Ventures	undisclosed
08/12/26	$36,000,000	Series A	97212 Ventures Fresh Fund IT-Farm Key 1 Capital M Ventures Merck KGaA NFX O.G. Venture Partners PsyMed Ventures Qumra Capital Tadmor Group TechAviv Founder Partners Vine Ventures	undisclosed